NO20065741L - Framgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser - Google Patents

Framgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser

Info

Publication number
NO20065741L
NO20065741L NO20065741A NO20065741A NO20065741L NO 20065741 L NO20065741 L NO 20065741L NO 20065741 A NO20065741 A NO 20065741A NO 20065741 A NO20065741 A NO 20065741A NO 20065741 L NO20065741 L NO 20065741L
Authority
NO
Norway
Prior art keywords
treatment
pathway
reagents
methods
disorders
Prior art date
Application number
NO20065741A
Other languages
English (en)
Inventor
Edward Roydon Jost-Price
Palaniyandi Manivasakam
Curtis Keith
Jane Staunton
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of NO20065741L publication Critical patent/NO20065741L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen omfatter behandling, forebygging og reduksjon av immuninflammatoriske forstyrrelser som omfatter kombinasjonen av et middel som øker signaleringsaktiviteten av en glukokortikoidreseptor (feks. glukokortikoidreseptor-agonist) og et middel som modulerer signaleringsaktiviteten av én eller flere signaleringsveier valgt fra NF-KB-veien, NFAT-veien, AP-l-veien og Elk-l-veien slik at sekresjon eller produksjon av proinflammatorisk cytokin eller hvilken som helst annen inflammatorisk respons, blir redusert. Videre tilveiebringes screeningsmetoder for å identifisere kandidatforbindelser og strategier anvendelige for behandling, forebygging eller reduksjon av slike lidelser.
NO20065741A 2004-05-17 2006-12-12 Framgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser NO20065741L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57175704P 2004-05-17 2004-05-17
PCT/US2005/017117 WO2005115455A2 (en) 2004-05-17 2005-05-16 Methods and reagents for the treatment of immunoinflammatory disorders

Publications (1)

Publication Number Publication Date
NO20065741L true NO20065741L (no) 2007-01-31

Family

ID=35451412

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065741A NO20065741L (no) 2004-05-17 2006-12-12 Framgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser

Country Status (12)

Country Link
US (1) US20050271661A1 (no)
EP (1) EP1781267A4 (no)
JP (1) JP2007538083A (no)
CN (1) CN1980649A (no)
AU (1) AU2005247403A1 (no)
BR (1) BRPI0511272A (no)
CA (1) CA2566861A1 (no)
IL (1) IL179227A0 (no)
MX (1) MXPA06013463A (no)
NO (1) NO20065741L (no)
TW (1) TW200605864A (no)
WO (1) WO2005115455A2 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
EP2338511A3 (en) * 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
WO2006060819A2 (en) * 2004-12-03 2006-06-08 The Regents Of The University Of California Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
JP5722524B2 (ja) * 2006-03-02 2015-05-20 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体活性を抑制することによる同種移植片の生存の延長
US7964585B2 (en) * 2006-03-14 2011-06-21 Case Western Reserve University Composition and method of treating peripheral neuropathy
US20080167277A1 (en) * 2006-12-29 2008-07-10 Charles Conrad Methods of treating skin disorders with caffeic acid analogs
EP2152276A4 (en) * 2007-05-09 2011-09-14 Traffick Therapeutics Inc SCREENING ASSAY FOR IDENTIFYING CORRECTORS FOR PROTEIN TRANSPORT TROUBLESHOOTING
KR101058136B1 (ko) * 2007-11-09 2011-08-24 신동헌 캡시에이트 또는 디하이드로캡시에이트의 신규한 용도
CA2724023C (en) * 2008-05-13 2014-02-18 Genmedica Therapeutics Sl Salicylate conjugates useful for treating metabolic disorders
WO2010036973A1 (en) * 2008-09-25 2010-04-01 Comgenrx, Inc. Treatment of hyperproliferative disorders using cardiac glycosides
US8450337B2 (en) * 2008-09-30 2013-05-28 Moleculin, Llc Methods of treating skin disorders with caffeic acid analogs
JP2012520342A (ja) * 2009-03-16 2012-09-06 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ 代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート
US20100239552A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Combination Therapies for Treating Metabolic Disorders
WO2010120726A1 (en) 2009-04-13 2010-10-21 The Feinstein Institute For Medical Research Treatment of inflammatory diseases by inhibiting cold- inducible rna-binding protein (cirp)
US10813917B2 (en) 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
CN103160560A (zh) * 2011-12-08 2013-06-19 清华大学 11β，17α，20β，21- 四羟基孕甾-1，4-二烯-3-酮及其制备方法
CA2862492A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
US20140275257A1 (en) * 2013-03-14 2014-09-18 Foundation for the State University of New York N-acetyl cysteine compositions in the treatment of systemic lupus erythematosus
WO2015048083A1 (en) 2013-09-24 2015-04-02 The Feinstein Institute For Medical Research Peptides inhibiting cold-inducible rna binding protein activity
WO2017192928A1 (en) * 2016-05-06 2017-11-09 Albany Medical College Treatment of rosacea with p38 and erk kinase pathway inhibitors
US20180006888A1 (en) * 2016-07-01 2018-01-04 Intel Corporation Analytically directed data collection in sensor network
JP2020505362A (ja) * 2017-01-19 2020-02-20 ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 免疫炎症性皮膚障害を予防または治療するための方法および医薬組成物
CN107156163A (zh) * 2017-07-14 2017-09-15 安徽海日生物科技有限公司 一种甲基二磺隆和双氟磺草胺复配可分散油悬浮剂及其制备方法
CN113545316B (zh) * 2020-04-24 2022-05-17 中国科学院上海药物研究所 血根碱在制备trpa1通道激动剂中的应用
WO2022061171A1 (en) * 2020-09-18 2022-03-24 Spring Discovery, Inc. Combination therapies with disulfiram
CN113876764B (zh) * 2021-10-29 2023-04-14 山东良福制药有限公司 包含维甲酸的药物组合物在制备治疗特发性血小板减少性紫癜的药物中的用途
CN117323442B (zh) * 2023-08-30 2024-05-03 广东医科大学 一种巨噬细胞靶向二氧化锰纳米系统的制备方法及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783664A (en) * 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
US6288089B1 (en) * 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
WO2000059900A1 (en) * 1999-04-01 2000-10-12 The Board Of Trustees Of The University Of Arkansas P38mapk inhibitor and uses thereof
HRP20040102A2 (en) * 2001-07-09 2004-10-31 Combinatorx Combinations for the treatment of inflammatory disorders
US20030157030A1 (en) * 2001-11-02 2003-08-21 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
US20040110755A1 (en) * 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
AU2003299196A1 (en) * 2002-09-24 2004-04-23 Combinatorx, Incorporated Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2004058246A1 (en) * 2002-12-17 2004-07-15 Pharmagenesis, Inc. Triptolide derivatives as immunomodulator and anticancer agents
US6943259B2 (en) * 2003-02-25 2005-09-13 Pharmagenesis, Inc. Halogenated triptolide derivatives as immunomodulators and anticancer agents
EP1675550A4 (en) * 2003-09-24 2007-10-10 Combinatorx Inc THERAPEUTIC DOSAGE DIAGRAMS FOR ADMINISTRATION OF MEDICINAL COMBINATIONS

Also Published As

Publication number Publication date
TW200605864A (en) 2006-02-16
WO2005115455A2 (en) 2005-12-08
US20050271661A1 (en) 2005-12-08
MXPA06013463A (es) 2007-03-01
JP2007538083A (ja) 2007-12-27
WO2005115455A3 (en) 2006-08-10
IL179227A0 (en) 2007-03-08
EP1781267A4 (en) 2009-03-11
AU2005247403A1 (en) 2005-12-08
CN1980649A (zh) 2007-06-13
EP1781267A2 (en) 2007-05-09
CA2566861A1 (en) 2005-12-08
BRPI0511272A (pt) 2007-12-04

Similar Documents

Publication Publication Date Title
NO20065741L (no) Framgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser
EP1943521A4 (en) METHOD FOR PREDICTING AND FORECASTING CANCER AND MONITORING CANCER THERAPY
NO20061906L (no) Terapeutisk middel for mesoteliom
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
NO20014986D0 (no) 4,5-diaryl-3(2H)-furanonderivater som cyklooksygenase-2- inhibitorer
NO20081198L (no) Fremgangsmate for a predikere eller monitorere en pasients respons til et medikament rettet mot en ErbB-reseptor
JP2009519986A5 (no)
NO20072955L (no) Fremgangsmate og anordning for vedlikehold av et heis- hhv rulletrappanlegg
NO20071272L (no) Modulatorer av muskarine reseptorer.
DK1510492T3 (da) Fremgangsmåde til afprövning af et elevatoranlæg og elevatoranlæg
Russo et al. Novel immune biomarkers in complex regional pain syndrome
EP1946116A4 (en) METHOD FOR PREDICTING AND FORECASTING CANCER AND MONITORING CANCER THERAPY
MX2025006125A (es) Detección y análisis mejorados de señales acústicas biológicas
WO2021110799A3 (en) Methods and device for the analysis of tissue samples
WO2006136174A3 (en) Methods and systems for assessing hearing ability
MA45801A1 (fr) Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine
NO20081014L (no) Sammensetninger
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
ATE457309T1 (de) Modulatoren von peripheren 5-ht-rezeptoren
EP1824498A4 (en) METHOD AND COMPOSITIONS FOR TREATING PROLIFERATIVE CELL DISEASES
WO2004045545A3 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
DE502004010073D1 (de) Doppelseitiger tourbillon
NO20041710D0 (no) Anordning og system for slukking av dekksbranner pa et skip.
WO2006024958A3 (en) Cannabinoid compositions and methods of use thereof
NO20072048L (no) Anvendelse av IL-17F for behandling og/eller forebygging av neurologiske sykdommer.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application